FL,   MZL

FDA grants priority review to lenalidomide and rituximab combination for the treatment of indolent NHL

On 26 February 2019, the US Food and Drug Administration (FDA) accepted a supplemental new drug application (sNDA) and granted priority review to the lenalidomide and rituximab (R2) regimen, for the treatment of patients with previously treated relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL).

The sNDA for the R2 regimen was based on the results from the multicenter, randomized, double-blind, phase III AUGMENT (NCT01938001) trial, which assessed the efficacy of the R2 regimen compared to single-agent rituximab therapy in patients with R/R FL or MZL. The results from this trial showed that according to independent review committee, progression-free survival in patients in the R2 arm was 39.4 months (95% CI, 22.9–not evaluable) compared to 14.1 months (95% CI, 11.4–16.7) in patients receiving rituximab monotherapy, with a median follow-up of 28.3 months. Further results from the AUGMENT study were presented at the 60th Annual Meeting of the American Society of Hematology (ASH), read more here.

According to the drug manufacturers, the R2 regimen “has the potential to offer patients with previously treated follicular lymphoma and marginal zone lymphoma a chemotherapy-free option”.

References
  1. TargetedOnc. Lenalidomide/Rituximab receives priority review designation from FDA for indolent non-Hodgkin lymphoma. https://www.targetedonc.com/news/lenalidomiderituximab-receives-priority-review-designation-from-fda-for-indolent-nonhodgkin-lymphoma [Accessed 2019 Feb 28]
Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!
100% of people found this article informative